Composition comprising human allogeneic dermal powder and platelet-rich plasma for treating musculoskeletal diseases, and method for preparing same
The combination of human allogeneic dermal powder and platelet-rich plasma effectively addresses the limitations of existing treatments for musculoskeletal disorders by reducing pain and promoting tendon regeneration, demonstrating superior efficacy in clinical trials.
Patent Information
- Application Number
- PCT/KR2024/006113
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-05-03
- Filing Date
- 2024-05-07
- Publication Date
- 2024-11-14
AI Technical Summary
Current treatments for musculoskeletal disorders, such as lateral epicondylitis, are inadequate in providing effective pain relief and promoting tendon regeneration, leading to chronic pain and reduced quality of life.
A pharmaceutical composition comprising human allogeneic dermal powder and platelet-rich plasma, administered via injection or gel form, which reduces tendon size and promotes structural regeneration.
Significantly improves pain perception and functional disability scores, with an 85% reduction in ruptured tendon size after 6 months, outperforming platelet-rich plasma alone in clinical trials.
Smart Images

Figure KR2024006113_14112024_PF_FP_ABST
Abstract
Description
Composition for treating musculoskeletal diseases comprising human allogeneic dermal powder and platelet-rich plasma and method for producing the same
[0001] The present invention relates to a composition for treating musculoskeletal diseases comprising human allogeneic dermal powder and platelet-rich plasma, and a method for producing the same.
[0002] Musculoskeletal disorders are health problems caused by factors such as repetitive movements, improper work posture, excessive use of force, and sports injuries, and are diseases that cause pain or damage to the ligaments, nerves, muscles, bones, tendons, intervertebral discs, and surrounding body tissues of the neck, shoulders, waist, limbs, and arms and legs.
[0003] The types of musculoskeletal disorders are very broad, including tendinopathies such as rotator cuff disease, lateral epicondylitis of the elbow, biceps tendonopathy, plantar fasciitis, and patellar tendonitis, as well as osteoarthritis, herniated discs, and muscle sprains.
[0004] Among these musculoskeletal disorders, epicondylitis is a syndrome that causes pain or local tenderness at the epicondyle origin of the elbow joint (the medial and lateral epicondyle origins, the point where the muscles that flex or extend the wrist originate), and is one of the most common causes of elbow joint pain. It occurs in people who excessively play sports that use their arms, such as tennis or golf, or who use their arms a lot for work. Lateral epicondylitis, also called 'tennis elbow,' refers to degenerative changes and inflammation that occur in the wrist extensor muscles, and medial epicondylitis, also called 'golfer's elbow,' refers to degenerative changes and inflammation that occur on the inner side of the elbow, which is the main origin of the wrist flexor muscles.
[0005] Lateral epicondylitis is a painful inflammation of the tendon on the outer elbow. It's commonly known as tennis elbow because it's caused by excessive force on the outside of the elbow during a backhand swing. It commonly occurs on the dominant arm, and is also common in sports other than tennis and golf, as well as in occupations that use the arms extensively, such as computer users, housewives, carpenters, and chefs. Lateral epicondylitis is more common than medial epicondylitis, with a prevalence of approximately 1% in the general adult population, while medial epicondylitis has a prevalence of approximately 0.1%.
[0006] Lateral epicondylitis mostly occurs acutely and often becomes chronic. When bending the fingers and wrist backward or resisting extension, patients complain of pain, numbness, and a feeling of sensitivity on the outside of the elbow. This pain is not limited to the outside of the elbow but can also radiate to the wrist.
[0007] The treatment principles for lateral epicondylitis can be summarized as pain management, inflammation reduction, promotion of natural soft tissue healing, muscle strength restoration, and return to activity. Most cases can be fully recovered with conservative treatment alone, but if chronic pain persists despite various treatments, surgical treatment may be considered.
[0008] Pain and decreased physical function caused by musculoskeletal disorders, including the aforementioned lateral epicondylitis, lower quality of life and reduce productivity. Clinical features of musculoskeletal disorders include pain, aching, stiffness, numbness, and movement disorders due to pulling sensations, and diagnosis is made through a comprehensive examination, X-rays, and other modalities. Treatments for musculoskeletal disorders include painkillers, steroids, procedures, surgery, extracorporeal shock wave therapy, acupuncture, moxibustion, cupping, herbal medicine, and Chuna therapy. Numerous treatments have been developed and implemented across traditional Korean medicine and medicine, but there is currently no single, truly effective treatment.
[0009] Against this backdrop, the inventors of the present invention have studied a method for alleviating, improving, or treating musculoskeletal diseases, and have completed the present invention by confirming that the administration of a mixture of acellular dermal matrix (human allogeneic dermis) and platelet-rich plasma improves function and pain in patients with musculoskeletal diseases, reduces the size of ruptured tendons, and structurally regenerates tendons.
[0010] [Prior Art Literature]
[0011] [Patent Document]
[0012] (Patent Document 1) Korean Patent Registration No. KR 10-2510792
[0013] The purpose of the present invention is to provide a pharmaceutical composition for preventing or treating musculoskeletal diseases, which comprises human allogeneic dermis and platelet-rich plasma.
[0014] Another object of the present invention is to provide a method for preventing or treating a musculoskeletal disease, comprising administering the pharmaceutical composition to a subject who has developed or is likely to develop a musculoskeletal disease.
[0015] Another object of the present invention is to provide a method for preparing a pharmaceutical composition for preventing or treating musculoskeletal diseases, which comprises a step of mixing human allogeneic dermis and platelet-rich plasma.
[0016] The advantages and features of the present invention, and the methods for achieving them, will become clearer with reference to the embodiments described in detail below together with the accompanying drawings. However, the present invention is not limited to the embodiments disclosed below and may be implemented in various different forms. These embodiments are provided solely to ensure that the disclosure of the present invention is complete and to fully inform those skilled in the art of the scope of the present invention, and the present invention is defined solely by the scope of the claims.
[0017] The terminology used herein is for the purpose of describing embodiments only and is not intended to limit the present invention. In this specification, the singular also includes the plural unless specifically stated otherwise. As used herein, the terms "comprises" and / or "comprising" do not exclude the presence or addition of one or more other components in addition to the mentioned components. Like reference numerals refer to like components throughout the specification, and "and / or" includes each and any combination of one or more of the mentioned components. Although "first", "second", etc. are used to describe various components, these components are not limited by these terms. These terms are only used to distinguish one component from another. Therefore, it should be understood that a first component mentioned below may also be a second component within the technical spirit of the present invention.
[0018] Unless otherwise defined, all terms (including technical and scientific terms) used herein may be used in their common sense to those skilled in the art to which the present invention pertains. Furthermore, terms defined in commonly used dictionaries are not to be interpreted ideally or excessively unless explicitly and specifically defined otherwise.
[0019] The present invention provides a pharmaceutical composition for preventing or treating musculoskeletal diseases, comprising human allogeneic dermis and platelet-rich plasma.
[0020] The human allogeneic dermis of the present invention may be in the form of a powder having a particle size of 50 to 150 μm, specifically 60 to 120 μm, and more specifically 70 to 110 μm.
[0021] The above human allogeneic dermal powder is a collagen powder with reduced immunity through an acellularization process and can be used for tissue reconstruction, etc.
[0022] The above human allogeneic dermis may also be described interchangeably with acellular dermal matrix (ADM). The above human allogeneic dermis refers to a dermal matrix isolated from a living tissue, preferably skin tissue, from which cells that may cause an immune rejection reaction have been removed, and collagen and elastin form its main components.
[0023] The platelet-rich plasma of the present invention contains 3 to 5 x 10 platelets. 8 / mL may be included.
[0024] The above platelet rich plasma (PRP) is not particularly limited as long as it is manufactured by a method commonly used in the field, and can be separated using a standard and consistent platelet component collection system. The platelet rich plasma may be autologous or allogeneic, and refers to plasma with a high platelet content, and is the plasma separated from whole blood using centrifugation, and is the plasma with the highest platelet content at the bottom. Platelet rich plasma injection can be used for regeneration of living tissue due to the secretion of growth factors within platelets.
[0025] The composition of the present invention may contain human allogeneic dermal powder and platelet-rich plasma in a volume ratio of 1:0.5 to 2, respectively.
[0026] In one specific embodiment of the present invention, the composition of the present invention is prepared by including 1 cc of human allogeneic dermal powder and 1 cc of platelet-rich plasma solution.
[0027] The composition of the present invention can reduce pain caused by tendon damage.
[0028] In a specific embodiment of the present invention, when the composition of the present invention was administered, the degree of pain perception on the VAS was significantly improved, and when analyzing the disability scores of the arm, shoulder, and hand, it was confirmed that clinical function was restored through a decrease in the DASH score.
[0029] The Visual Analog Scale (VAS) is a method of assessing pain by giving patients a scale indicating their level of pain and asking them to select the facial expression that best matches their level of pain, or by having a specialist observe the patient's facial expression. This method measures pain by observing a continuous gradation from none, mild, moderate, and severe.
[0030] The Disabilities of the Arm, Shoulder, and Hand (DASH) score assessment is a questionnaire consisting of 38 items in total, including 30 items assessing movement performance, 4 optional work-related questions, and 4 sports and / or artistic activity-related questions. Each item is scored on a 5-point scale (1: no difficulty, 2: some difficulty, 3: moderate difficulty, 4: very difficult, 5: unable to do at all). The DASH is a highly reliable and valid assessment tool used to assess upper limb movement impairment in patients with musculoskeletal disorders.
[0031] The composition of the present invention can regenerate tendon tissue.
[0032] In a specific embodiment of the present invention, the proportion of patients whose ruptured tendon size was reduced as a result of MRI analysis when the composition of the present invention was administered was 85%, which was significantly higher than the 50% in the group that only received platelet-rich plasma injection, indicating that the composition of the present invention is excellent in regenerating damaged tendon tissue.
[0033] The musculoskeletal disease of the present invention may be at least one selected from the group consisting of lateral epicondylitis, medial epicondylitis, plantar fasciitis, rotator cuff tendon disease, Achilles tendon disease, patellar tendon disease, tenosynovitis, tendinopathy, tendinitis, tenosynovitis, tendon injury, tendon strain, tendon rupture, tendon tear, tendon avulsion, cruciate ligament injury, ankle ligament injury, collateral ligament injury, ligament rupture, ligament sprain, chondromalacia, osteoarthritis, osteoarthritis, chondrodysplasia, degenerative arthritis, rheumatoid arthritis, osteomalacia, osteitis fibrosa, and aplastic bone disease.
[0034] The above musculoskeletal disorders are health disorders caused by factors such as repetitive movements, inappropriate work postures, excessive use of force, sports injuries, vibrations, and temperatures, and refer to diseases that cause pain or impaired function in the ligaments, nerves, muscles, bones, tendons, intervertebral discs, and surrounding body tissues of the neck, shoulders, waist, and limbs.
[0035] The pharmaceutical composition according to the present invention can be formulated as an injection solution or a gel for local transplantation, and can treat musculoskeletal diseases more quickly and effectively than existing oral therapeutic drugs by directly administering it through the skin rather than orally.
[0036] The injection solution of the present invention may additionally include a sterilized aqueous solution, non-aqueous solvent, suspension, emulsion, lyophilized preparation, etc. that are harmless to the human body. Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate.
[0037] The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount.
[0038] The above pharmaceutically effective amount means an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment, and the effective dosage level can be determined according to factors including the type and severity of the individual, age, sex, progression of the disease, activity of the drug, sensitivity to the drug, time of administration, route of administration and excretion rate, duration of treatment, concurrently used drugs, and other factors well known in the medical field. The composition of the present invention can be administered as an individual therapeutic agent or in combination with other therapeutic agents, and can be administered sequentially or simultaneously with conventional therapeutic agents. And it can be administered singly or in multiple doses.
[0039] The above composition can be administered to mammals such as rats, mice, livestock, and humans via various routes. All modes of administration are conceivable, and for example, it can be administered by tendon or ligament injection, or intramuscular injection.
[0040] The treatment of the present invention refers to an approach aimed at achieving beneficial or desirable clinical outcomes. For the purposes of the present invention, beneficial or desirable clinical outcomes include, but are not limited to, alleviation of symptoms, reduction in the extent of the disease, stabilization (i.e., non-worsening) of the disease state, delay or reduction in the rate of disease progression, improvement or temporary relief and remission (partial or total) of the disease state, whether detectable or undetectable.
[0041] The above treatment includes not only the treatment required for preventable disorders but also for disorders that have already occurred. Alleviating a disease means reducing the extent of the disease and / or undesirable clinical symptoms, and / or slowing or prolonging the time course of progression, compared to a case without treatment.
[0042] In addition, the present invention provides a method for preventing or treating a musculoskeletal disease, comprising a step of administering the pharmaceutical composition to a subject who has developed or is likely to develop a musculoskeletal disease.
[0043] The above musculoskeletal disease may be at least one selected from the group consisting of lateral epicondylitis, medial epicondylitis, plantar fasciitis, rotator cuff tendon disease, Achilles tendon disease, patellar tendon disease, tenosynovitis, tendinopathy, tendinitis, tenosynovitis, tendon injury, tendon strain, tendon rupture, tendon tear, tendon avulsion, cruciate ligament injury, ankle ligament injury, collateral ligament injury, ligament rupture, ligament sprain, chondromalacia, osteoarthritis, osteoarthritis, chondrodysplasia, degenerative arthritis, rheumatoid arthritis, osteomalacia, osteitis fibrosa, and aplastic bone disease, but is not limited thereto.
[0044] The above object means all animals, including rats, mice, and livestock, including humans, that can develop or be induced with musculoskeletal diseases.
[0045] Administration of the present invention means introducing the pharmaceutical composition into a subject.
[0046] Prevention of the present invention refers to any action that inhibits or delays the onset of a musculoskeletal disease by administering the pharmaceutical composition.
[0047] The treatment of the present invention refers to all actions that improve or benefit the symptoms of musculoskeletal diseases by administering the pharmaceutical composition.
[0048] In addition, the present invention provides a method for preparing a pharmaceutical composition for preventing or treating musculoskeletal diseases, comprising a step of mixing human allogeneic dermis and platelet-rich plasma.
[0049] The above human allogeneic dermis refers to a dermal matrix separated from a living tissue, preferably skin tissue, from which cells that may cause an immune rejection reaction have been removed, and collagen and elastin are the main components.
[0050] The above platelet rich plasma (PRP) may be autologous or allogeneic, and refers to plasma containing a large number of platelets, which is the plasma separated from whole blood using centrifugation and contains the most platelets at the bottom.
[0051] In a specific embodiment of the present invention, a method for preparing a pharmaceutical composition for preventing or treating a musculoskeletal disease of the present invention comprises the step of mixing 1 cc of dry human allograft dermis powder and 1 cc of platelet-rich plasma solution by injecting them into a syringe.
[0052] The present invention provides a composition for treating musculoskeletal diseases, including human allogeneic dermal powder and platelet-rich plasma, and a method for preparing the same. The composition can be usefully used as a pharmaceutical composition for preventing or treating musculoskeletal diseases by improving function and pain, reducing the size of a ruptured tendon, and inducing structural regeneration of the tendon when administered to a patient with a musculoskeletal disease.
[0053] Figure 1 is a diagram showing the results of performing a total receiver tendon injection ultrasound.
[0054] Figure 2 is a diagram showing the results of MRI analysis before and 6 months after injection of a composition prepared by including the human allogeneic dermal powder and platelet-rich plasma of the present invention into a partial rupture site of the anterior cruciate ligament (case 1).
[0055] Figure 3 is a diagram showing the results of MRI analysis before and 6 months after injection of a composition prepared by including the human allogeneic dermal powder and platelet-rich plasma of the present invention into the site of partial rupture of the anterior cruciate ligament (case 2).
[0056] Hereinafter, the present invention will be described in more detail through the following examples and experimental examples. However, the scope of the present invention is not limited to the following examples and experimental examples, but includes modifications of technical concepts equivalent thereto.
[0057] Manufacturing Example 1. Preparation of materials
[0058] Prepare human allograft dermis powder and platelet-rich plasma. More specifically, prepare 1 cc of dry human allograft dermis powder and 1 cc of platelet-rich plasma solution each in a 3 cc syringe.
[0059] Manufacturing Example 2. Manufacturing of a mixed therapeutic agent of human allogeneic dermal powder and platelet-rich plasma
[0060] In the above manufacturing example 1, each of the human allogeneic dermal powder and platelet-rich plasma prepared in a 3 cc syringe is connected to a connector suitable for the syringe inlet.
[0061] Begin mixing by shooting the platelet-rich plasma into the syringe containing the human allograft dermal powder. Mix by shooting 5 to 10 times.
[0062] The mixed solution is typically about 1.5 cc and shaken well to remove air bubbles. The mixed treatment agent is then connected to a 21-gauge needle.
[0063] Comparative Example 1. Preparation of an injection containing only platelet-rich plasma
[0064] Prepare 1 cc of platelet-rich plasma solution in each 3 cc syringe, and prepare an injection containing only platelet-rich plasma.
[0065] Example 1. Analysis of the Visual Analogue Pain Assessment Scale
[0066] The clinical results were evaluated by administering the injections prepared in the above manufacturing examples and comparative examples to damaged musculoskeletal tissues of patients diagnosed with lateral epicondylitis by a specialist.
[0067] More specifically, a total of 40 patients confirmed to have ruptured common extensor tendon (CET) of the elbow were randomly assigned to receive a mixed injection of human allogeneic dermal powder and platelet-rich plasma prepared in the above manufacturing example to 20 patients, and an injection containing only platelet-rich plasma prepared in the above comparative example to 20 patients.
[0068] The Visual Analog Scale (VAS) is a method of assessing pain by giving patients a scale indicating their level of pain and asking them to select the facial expression that best matches their level of pain, or by having a physician observe the patient's facial expression. This method measures pain by observing a continuum of perceived pain ranging from none, mild, moderate, and severe.
[0069] The average follow-up period was 13.1 months, and the pain scores of the group administered the mixed injection of human allogeneic dermal powder and platelet-rich plasma of the present invention (manufacturing example) and the group administered the injection of platelet-rich plasma (comparative example) were compared and analyzed.
[0070] Example 2. Analysis of disability scores for the arm, shoulder, and hand.
[0071] The clinical results were evaluated by administering the injections prepared in the above manufacturing examples and comparative examples to damaged musculoskeletal tissues of patients diagnosed with lateral epicondylitis by a specialist.
[0072] More specifically, a total of 40 patients confirmed to have ruptured common extensor tendon (CET) of the elbow were randomly assigned to receive a mixed injection of human allogeneic dermal powder and platelet-rich plasma prepared in the above manufacturing example to 20 patients, and an injection containing only platelet-rich plasma prepared in the above comparative example to 20 patients.
[0073] Disabilities of the arm, shoulder, and hand (DASH) scores were analyzed.
[0074] The DASH is a 38-item questionnaire consisting of 30 items assessing motor skills, four optional work-related items, and four sports and / or artistic activities. Each item is scored on a 5-point scale (1: no difficulty, 2: some difficulty, 3: moderate difficulty, 4: very difficult, 5: completely unable). The DASH is a reliable and valid assessment tool that can be used to assess upper limb movement impairments in patients with musculoskeletal disorders.
[0075] The average follow-up period was 13.1 months, and the DASH scores of the group administered the mixed injection of human allogeneic dermal powder and platelet-rich plasma of the present invention (manufacturing example) and the group administered the injection of platelet-rich plasma (comparative example) were compared and analyzed.
[0076] Example 3. Tennis elbow recovery analysis
[0077] The clinical results were evaluated by administering the injections prepared in the above manufacturing examples and comparative examples to damaged musculoskeletal tissues of patients diagnosed with lateral epicondylitis by a specialist.
[0078] More specifically, a total of 40 patients confirmed to have ruptured common extensor tendon (CET) of the elbow were randomly assigned to receive a mixed injection of human allogeneic dermal powder and platelet-rich plasma prepared in the above manufacturing example to 20 patients, and an injection containing only platelet-rich plasma prepared in the above comparative example to 20 patients.
[0079] To analyze tennis elbow recovery, the Nirschl score was measured to assess pain relief, and the PRTEE score was measured to assess functional improvement.
[0080] The average follow-up period was 13.1 months, and the Nirschl score and PRTEE score of the group administered the mixed injection of human allogeneic dermal powder and platelet-rich plasma of the present invention (manufacturing example) and the group administered the injection of platelet-rich plasma (comparative example) were compared and analyzed.
[0081] Example 4. Comparative analysis of the size of ruptured tendons in MRI.
[0082] The clinical results were evaluated by administering the injections prepared in the above manufacturing examples and comparative examples to damaged musculoskeletal tissues of patients diagnosed with lateral epicondylitis by a specialist.
[0083] More specifically, a total of 40 patients confirmed to have ruptured common extensor tendon (CET) of the elbow were randomly assigned to receive a mixed injection of human allogeneic dermal powder and platelet-rich plasma prepared in the above manufacturing example to 20 patients, and an injection containing only platelet-rich plasma prepared in the above comparative example to 20 patients.
[0084] Magnetic resonance imaging (MRI) analysis was performed 6 months after injection.
[0085] Example 5. Statistical processing
[0086] All experiments were repeated three times, and the average values were analyzed using Duncan's multiple range test one-way ANOVA in SPSS software (Statistical Package for Social Science, Chicago, IL, USA), and p<0.05 was considered statistically significant.
[0087] Experimental Example 1. Confirmation of improvement in function and pain in patients diagnosed with lateral epicondylitis.
[0088] Clinical outcomes were evaluated by administering the injections prepared in the above-mentioned manufacturing examples and comparative examples to damaged musculoskeletal tissues in patients diagnosed with lateral epicondylitis by a specialist. The average follow-up period was 13.1 months.
[0089] 1-1. Results of analysis of the visual analog pain assessment scale
[0090] The Visual Analog Scale (VAS) is a method of assessing the degree of pain felt, and is measured based on a continuous change in the pain perceived by patients from none, mild, moderate, and severe.
[0091] The pain scores of the group administered the mixed injection of human allogeneic dermal powder and platelet-rich plasma (ADM + PRP) of the present invention (manufacturing example) and the group administered the injection of platelet-rich plasma (PRP) (comparative example) were compared and analyzed.
[0092] As a result, it was confirmed that the VAS score of the ADM + PRP group of the present invention (a mixed injection group of human allogeneic dermal powder and platelet-rich plasma; manufacturing example) decreased from 7.1 to 0.8, and the VAS score of the PRP group (a injection group of platelet-rich plasma; comparative example) decreased from 6.8 to 0.8 (p<0.001).
[0093] Through this, the results of analyzing the visual analog assessment scale for pain showed that the pain level of the VAS was significantly improved in both groups.
[0094] 1-2. Analysis results of disability scores for arms, shoulders, and hands
[0095] Disabilities of the arm, shoulder, and hand (DASH) scores were analyzed.
[0096] DASH is a highly reliable and valid analysis tool for assessing impairments in upper limb movement in patients with musculoskeletal disorders.
[0097] The DASH scores of the group administered the mixed injection of human allogeneic dermal powder and platelet-rich plasma (ADM + PRP) of the present invention (manufacturing example) and the group administered the injection of platelet-rich plasma (PRP) (comparative example) were compared and analyzed.
[0098] As a result, it was confirmed that the DASH score of the ADM + PRP group of the present invention (a mixed injection group of human allogeneic dermal powder and platelet-rich plasma; manufacturing example) decreased from 23.2 to 1.9, and the DASH score of the PRP group (a injection group of platelet-rich plasma; comparative example) decreased from 24.0 to 1.7 (p<0.001).
[0099] Through this, the analysis of disability scores of the arm, shoulder, and hand showed that the function was significantly improved through a decrease in the DASH score in both groups (p<0.001).
[0100] 1-3. Tennis Elbow Recovery Analysis
[0101] To analyze tennis elbow recovery, the Nirschl score was measured to assess pain relief, and the PRTEE score was measured to assess functional improvement.
[0102] The Nirschl score and PRTEE score of the group (manufacturing example) administered the mixed injection of human allogeneic dermal powder and platelet-rich plasma (ADM + PRP) of the present invention and the group (comparative example) administered the injection of platelet-rich plasma (PRP) were compared and analyzed.
[0103] As a result, it was confirmed that the PRTEE score of the ADM + PRP group of the present invention (a mixed injection group of human allogeneic dermal powder and platelet-rich plasma; manufacturing example) decreased from 90.1 to 4.6, and the PRTEE score of the PRP group (a injection group of platelet-rich plasma; comparative example) decreased from 91.2 to 4.7 (p<0.001).
[0104] In addition, it was confirmed that the Nirschl score of the ADM + PRP group of the present invention (a mixed injection group of human allogeneic dermal powder and platelet-rich plasma; manufacturing example) decreased from 6.0 to 1.1, and the Nirschl score of the PRP group (a injection group of platelet-rich plasma; comparative example) decreased from 6.2 to 1.0 (p<0.001).
[0105] Through this, the Nirschl score for evaluating pain relief and the PRTEE score for evaluating functional improvement were measured to analyze the recovery of tennis elbow, and the results showed that pain was significantly relieved and function was improved in both groups.
[0106] In addition, the present invention suggests that the mixed therapeutic agent comprising the human allogeneic dermal powder and platelet-rich plasma is effective in alleviating, improving, and treating musculoskeletal diseases.
[0107] Experimental Example 2. Confirmation of structural regeneration of ruptured tendons.
[0108] Clinical outcomes were evaluated by administering the injections prepared in the above-mentioned examples and comparative examples to injured musculoskeletal tissues in patients diagnosed with lateral epicondylitis by a specialist (Fig. 1). MRI (magnetic resonance imaging) analysis was performed 6 months after injection.
[0109] As a result, it was confirmed that the size of the ruptured tendon was significantly reduced 6 months after injecting the mixed treatment including the human allogeneic dermal powder and platelet-rich plasma manufactured in the manufacturing example of the present invention (Figs. 2 and 3).
[0110] Additionally, the proportion of patients with a decrease in the size of the ruptured tendon was 85% when administered a mixed treatment comprising the human allogeneic dermal powder and platelet-rich plasma manufactured in the manufacturing example of the present invention. On the other hand, when administered a treatment comprising only the platelet-rich plasma manufactured in the comparative example, it was 55% (p<0.05).
[0111] Through this, it is shown that administration of a mixed treatment comprising the human allograft dermal powder of the present invention and platelet-rich plasma has an excellent effect on structural regeneration of the tendon in patients with ruptured common extensor tendon of the elbow.
[0112] While the embodiments of the present invention have been described above, the present invention is not limited to the above embodiments, but can be manufactured in various different forms. Those skilled in the art will understand that the present invention can be implemented in other specific forms without altering the technical spirit or essential characteristics of the present invention. Therefore, the embodiments described above should be understood to be illustrative in all respects and not restrictive.
Claims
1. A pharmaceutical composition for preventing or treating musculoskeletal diseases comprising human allogeneic dermis and platelet-rich plasma.
2. In paragraph 1, A pharmaceutical composition characterized in that the human allogeneic dermis is in the form of a powder having a particle size of 50 to 150 μm.
3. In paragraph 1, The above platelet-rich plasma contains 3 to 5 x 10 platelets. 8 A pharmaceutical composition comprising / mL.
4. In paragraph 1, A pharmaceutical composition characterized in that the composition reduces pain caused by tendon damage.
5. In paragraph 1, A pharmaceutical composition characterized in that the composition regenerates tendon tissue.
6. In paragraph 1, A pharmaceutical composition characterized in that the above musculoskeletal disease is at least one selected from the group consisting of lateral epicondylitis, medial epicondylitis, plantar fasciitis, rotator cuff tendon disease, Achilles tendon disease, patellar tendon disease, tenosynovitis, tendinopathy, tendinitis, tenosynovitis, tendon injury, tendon strain, tendon rupture, tendon tear, tendon avulsion, cruciate ligament injury, ankle ligament injury, collateral ligament injury, ligament rupture, ligament sprain, chondromalacia, osteoarthritis, osteoarthritis, chondrodysplasia, degenerative arthritis, rheumatoid arthritis, osteomalacia, osteitis fibrosa, and aplastic bone disease.
7. In paragraph 1, A pharmaceutical composition characterized in that the composition is formulated as an injection or a gel for local transplantation.
8. A method for preventing or treating a musculoskeletal disease, comprising administering the pharmaceutical composition of paragraph 1 to a subject other than a human who has developed or is likely to develop a musculoskeletal disease.
9. In paragraph 8, A method for preventing or treating a musculoskeletal disease, characterized in that the musculoskeletal disease is at least one selected from the group consisting of lateral epicondylitis, medial epicondylitis, plantar fasciitis, rotator cuff tendon disease, Achilles tendon disease, patellar tendon disease, tenosynovitis, tendinopathy, tendinitis, tenosynovitis, tendon injury, tendon strain, tendon rupture, tendon tear, tendon avulsion, cruciate ligament injury, ankle ligament injury, collateral ligament injury, ligament rupture, ligament sprain, chondromalacia, osteoarthritis, osteoarthritis, chondrodysplasia, degenerative arthritis, rheumatoid arthritis, osteomalacia, osteitis fibrosa, and aplastic bone disease.
10. A method for producing a pharmaceutical composition for preventing or treating musculoskeletal diseases, comprising a step of mixing human allogeneic dermis and platelet-rich plasma.
Citation Information
Patent Citations
Composite hydrogel for promoting wound healing and preparation method and application thereof
CN114225096A
Composition and Methods For Repair of Connective Tissue
US20110111028A1
